EUCTR2006-001263-32-DE进行中（未招募）不适用
Phase III study to evaluate the anti-mycotic efficacy of a topical Abafungin formulation in patients with tinea pedis - N.A.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 375
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •·man or woman aged 18 to 75 years;
- •·presence of interdigital tinea pedis caused by dermatophytes on one or both feet, characterized by clinical evidence of involvement of more than one interdigital space and at least moderate erythema (at least score 2), and moderate scaling (at least score 2);
- •·a confirmatory microscopic demonstration of fungal elements;
- •·the physical examination must be without other disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study;
- •·sexually active females of childbearing potential should use a medically accepted contraceptive regimen: systemic contraceptive (oral, implant, injection), diaphragm with intravaginal spermicide, cervical cap, intrauterine device (IUD), condom with intravaginal spermicide, or be surgically sterile (hysterectomy or tubal ligation);
- •·written informed consent obtained.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •·received treatments like foot or shoe powders, pharmaceutical and cosmetic topicals (e.g. creams/gels, except for washing products) or topical anti-fungal therapy of the feet within 30 days before study entry, oral antifungal therapies within three months before study entry (8 months for oral terbinafine), systemic antibiotic or corticosteroid treatment, topical corticosteroids within 30 days before study entry, radiation therapy and/or anti-neoplastic agents within one year before study entry;
- •·receiving systemic therapy with cytotoxic or immunosuppressive drugs either concurrently or within 12 weeks before the baseline visit;
- •·receiving potassium permanganate drugs either concurrently or within 1 week before the baseline visit;
- •·use of antibacterial, antiviral or antihelminthic drugs concurrently or within 2 weeks before the baseline visit.
- •·evidence of drug or alcohol abuse;
- •·pregnancy or nursing;
- •·have symptoms of a clinically significant illness, or known laboratory value deviation, that may influence the safety of the patient, or the outcome of the study in the 30 days before and during the study;
- •· are known to be immunodeficient;
- •·have symptoms of a diabetic foot or neuropathies at foot/feet;
- •·have foot psoriasis, corn and/or callus involving any interdigital web spaces, atopic or contact dermatitis;
- •·widespread dermatophytoses, plantar / moccasin type tinea pedis, hyperkeratotic tinea pedis, tinea pedis or systemic fungal infection requiring systemic treatment, onychomycosis, tinea corporis, tinea cruris or tinea capitis, mucocutaneous candidiasis or bacterial skin infection;
- •·participation in another clinical trial involving pharmaceutical products in the 30 days preceding the study and during the study;
- •·known allergic reactions or known hypersensitivity to components of the study medications;
- •·in the opinion of the investigator or physician performing the initial examination the patient should not participate in the study, e. g. due to probable noncompliance or inability to answer questions or to assess tolerability of the study drug or to understand the study and give adequately informed consent.
研究者
相似试验
进行中（未招募）
1 期
Phase III study to evaluate the anti-mycotic efficacy of a topical Abafungin formulation in patients with tinea pedis - N.A.Patients with tinea pedis interdigitalisEUCTR2006-001263-32-GBYork Pharma GmbH375
进行中（未招募）
1 期
Phase III study to evaluate the anti-mycotic efficacy of a topical Abafungin formulation in patients with tinea pedis - N.A.EUCTR2006-001263-32-ISYork Pharma GmbH375
进行中（未招募）
不适用
Confirmatory study to evaluate the efficacy and safety of chondroitin sulphate and glucosamine sulphate in combination in the treatment of patients with osteoarthritis of the knee compared to placebo.EUCTR2013-000444-26-ESTedec-Meiji Farma, S.A.
已完成
3 期
A study of Dydrogesterone Tablets for treatment of endometriosis in womeCTRI/2023/03/050698Zydus Healthcare Limited228
已完成
不适用
Efficacy and tolerability of EPs® 7630 in patients with chronic obstructive pulmonary disease (COPD)Chronic obstructive pulmonary disease (COPD)RespiratoryOther chronic obstructive pulmonary diseaseISRCTN01681733Dr. Willmar Schwabe GmbH & Co. KG (Germany)200